Bottom-Up EquitiesDaily Briefs

Equity Bottom-Up: Softbank Group, Golden Agri Resources, Belite Bio, Comfortdelgro Corp, Beijing Airdoc Technology and more

In today’s briefing:

  • Softbank – Director Shuffling At The AGM
  • Smartkarma Corporate Webinar | Golden Agri-Resources: From Seed to Shelf
  • Belite Bio (BLTE US): Lead Drug Candidate Tapping into Niche Market with Massive Opportunity
  • Comfortdelgro (CD): When to Take Off?
  • Beijing Airdoc Technology (2251.HK) – Not Optimistic About Turning Loss into Profit

Softbank – Director Shuffling At The AGM

By Mio Kato

  • With Softbank’s AGM coming up we examine some of the curious events that surround the firm as usual. 
  • Following in the footsteps of former governance director Yuko Kawamoto, VC founder Lip-Bu Tan has also penned a curious resignation message.  
  • Then there are the continuing questions surrounding Kenneth Siegel and his reappointment is not guaranteed in our view.

Smartkarma Corporate Webinar | Golden Agri-Resources: From Seed to Shelf

By Smartkarma Research

For our next Corporate Webinar, we are glad to welcome Golden Agri Resources (GGR SP) Director, Investor Relations, Richard Fung. In the upcoming Webinar, Richard will share a short company presentation, after which he will engage in a fireside chat with Smartkarma Analyst Angus Mackintosh. A live Q&A session will follow.

The Corporate Webinar will be hosted on Tuesday, 5 July 2022, 17:00 SGT.

Listed on the Singapore Exchange since 1999, Golden Agri-Resources Ltd (GAR) is one of the leading integrated palm oil plantation companies in the world, with a market capitalisation of US$2.6 billion as of 31 May 2022. During 2021, it generated revenue of over US$10 billion and underlying profit of US$603 million. GAR’s integrated operations focus on the technology-driven production and distribution of an extensive portfolio of palm-based products.

GAR encompasses an efficient end-to-end supply chain, from responsible production to global delivery. It cultivates 536 thousand hectares of palm oil plantations in Indonesia, including plasma smallholders; harvesting and extracting fresh fruit bunches into crude palm oil and palm kernel; processing into a broad range of value-added products such as cooking oil, margarine, shortening, biodiesel, and oleochemicals.

GAR has a global market presence with destination refining, ex-tank operations, and sales representative offices in several markets. GAR’s products are sold globally to approximately 100 countries. GAR also has complementary businesses such as soybean-based products in China, sunflower-based products in India, and sugar businesses.

Corporate Webinars by Smartkarma Corporate Solutions feature discussions with IROs and Executives, discussing their companies, the challenges they face, and the opportunities in their sectors and markets.

Belite Bio (BLTE US): Lead Drug Candidate Tapping into Niche Market with Massive Opportunity

By Tina Banerjee

  • Belite Bio (BLTE US) shares jumped 383% from its IPO price of $6 (announced in late April). Its lead candidate LBS-008 is in clinical trial for currently untreatable eye diseases.
  • LBS-008 continues to be well-tolerated. Interim safety and preliminary efficacy data from ongoing two-year phase 2 trial remained positive in Stargardt disease.
  • Belite is well-funded to commercialize its pipeline. With the progression of the clinical trial and more data readouts, we believe further stream is left in Belite Bio’s share price.

Comfortdelgro (CD): When to Take Off?

By Henry Soediarko

  • The number of visitors arriving in Singapore went up by almost 8x YoY and rail and bus ridership already hit 78% of the pre-pandemic level.
  • Won a bid to provide public transport in Darwin, Australia for the next 6 years, transporting approximately 5.7 million passengers annually (similar to Singapore’s population). 
  • As COE > SGD 100,000, the incentive to own a car in Singapore is even less and is a positive for public transport operators like Comfortdelgro Corp (CD SP) .

Beijing Airdoc Technology (2251.HK) – Not Optimistic About Turning Loss into Profit

By Xinyao (Criss) Wang

  • Without entering NRDL and public hospital markets, Airdoc’s core product Airdoc-AIFUNDUS would be hard to generate solid performance due to its high pricing but limited value to patients and doctors.
  • Due to lockdown/pandemic, we lowered our forecast on revenue growth/gross margin in 2022. As competition intensified, Airdoc’s revenue growth and margin could be significantly reduced in the coming years. 
  • The biggest concern for Airdoc is the commercialization prospects. The real turning point for AI medical imaging has not arrived. We are not optimistic that Airdoc will end up profitable. 

Related tickers: Softbank Group (9984.T), Golden Agri Resources (GAGR.SI), Comfortdelgro Corp (CMDG.SI)

Before it’s here, it’s on Smartkarma